Zymeworks Inc. Common Stock (NASDAQ:ZYME) — Market Cap & Net Worth
Market Cap & Net Worth: Zymeworks Inc. Common Stock (ZYME)
Zymeworks Inc. Common Stock (NASDAQ:ZYME) has a market capitalization of $1.73 Billion ($1.73 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6804 globally and #2051 in its home market, demonstrating a -0.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zymeworks Inc. Common Stock's stock price $23.14 by its total outstanding shares 74836534 (74.84 Million). Review Zymeworks Inc. Common Stock balance sheet liabilities to assess the company's total debt and financial obligations.
Zymeworks Inc. Common Stock Market Cap History: 2017 to 2026
Zymeworks Inc. Common Stock's market capitalization history from 2017 to 2026. Data shows growth from $568.24 Million to $1.73 Billion (6.51% CAGR).
Index Memberships
Zymeworks Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.07% | #180 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #738 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.10% | #114 of 263 |
Weight: Zymeworks Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zymeworks Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zymeworks Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.36x
Zymeworks Inc. Common Stock's market cap is 14.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $568.24 Million | $51.76 Million | -$10.41 Million | 10.98x | N/A |
| 2018 | $1.10 Billion | $53.02 Million | -$36.56 Million | 20.72x | N/A |
| 2019 | $3.40 Billion | $29.54 Million | -$145.44 Million | 115.15x | N/A |
| 2020 | $3.54 Billion | $38.95 Million | -$180.55 Million | 90.80x | N/A |
| 2021 | $1.23 Billion | $26.68 Million | -$211.84 Million | 45.97x | N/A |
| 2022 | $588.22 Million | $412.48 Million | $124.34 Million | 1.43x | 4.73x |
| 2023 | $777.55 Million | $76.01 Million | -$118.67 Million | 10.23x | N/A |
| 2024 | $1.10 Billion | $76.30 Million | -$122.69 Million | 14.36x | N/A |
Competitor Companies of ZYME by Market Capitalization
Companies near Zymeworks Inc. Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to Zymeworks Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Zymeworks Inc. Common Stock Historical Marketcap From 2017 to 2026
Between 2017 and today, Zymeworks Inc. Common Stock's market cap moved from $568.24 Million to $ 1.73 Billion, with a yearly change of 6.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.73 Billion | -12.12% |
| 2025 | $1.97 Billion | +79.85% |
| 2024 | $1.10 Billion | +40.90% |
| 2023 | $777.55 Million | +32.19% |
| 2022 | $588.22 Million | -52.04% |
| 2021 | $1.23 Billion | -65.32% |
| 2020 | $3.54 Billion | +3.96% |
| 2019 | $3.40 Billion | +209.67% |
| 2018 | $1.10 Billion | +93.33% |
| 2017 | $568.24 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Zymeworks Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.73 Billion USD |
| MoneyControl | $1.73 Billion USD |
| MarketWatch | $1.73 Billion USD |
| marketcap.company | $1.73 Billion USD |
| Reuters | $1.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more